Literatur
-
1
Adamis A P, Shima T S.
The role of vascular endothelial growth factor in ocular disease.
Retina.
2005;
25
111-118
-
2
Augustin A J, Schmidt-Erfurth U.
Verteporfin therapy with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration.
Ophthalmology.
2006;
113
14-22
-
3
Avery R L, Pieramici D J, Rabena M D. et al .
Intravitreal bevacizumab (avastin) for neovascular age-related macular degeneration.
Ophthalmology.
2006;
113
363-372
-
4
Bernatchez P N, Rollin S, Soker S. et al .
Relative effects of VEGF‐A and VEGF‐C on endothelial cell proliferation, migration and PAF synthesis: Role of neuropilin-1.
J Cell Biochem.
2002;
85
629-639
-
5
Bird A C.
Age-related macular disease.
Br J Ophthalmol.
1996;
80
1-2
-
6
Bressler S B, Pieramici D J, Koester J M. et al .
Natural history of minimally classic subfoveal choroidal neovascular lesions in the treatment of age-related macular degeneration with photodynamic therapy (TAP) Investigation: outcomes potentially relevant to management. TAP Report No. 6.
Arch Ophthalmol.
2004;
122
325-329
-
7
Challa J, Gillies M, Penfold P, Gyory J, Hunyor A, Billson F.
Exsudative macular degeneration and intravitreal triamcinolone: 18 month follow up.
Aust N Z J Ophthalmol.
1998;
26
188-192
-
8
Chen Y, Wiesmann C, Fuh G. et al .
Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen.
J Mol Biol.
1999;
293
685-881
-
9
Ciulla T A, Criswell M H, Danis R P, Hill T E.
Intravitreal triamcinolone acetonide inhibits choroidal neovascularisation in a laser-treated rat model.
Arch Ophthalmol.
2001;
119
399-404
-
10
Cursiefen C, Chen L, Borges L P. et al .
VEGF‐A stimulates lymphangiogenesis and hemangiogenesis in inflammatory neovascularization via macrophage recruitment.
J Clin Invest.
2004;
113
1040-1050
-
11 D'Amico D J. Results of the second year of Macugen for the treatment of neovascular AMD (V.I.S.I.O.N). Abstract presented at the American Society of Retinal Specialists Meeting, Montreal. 2005
-
12
Danis R P, Ciulla T A, Pratt L M, Anliker W.
Intravitreal triamcinolone acetonide in exsudative age-related macular degeneration.
Retina.
2000;
20
244-250
-
13
Ferrara N, Gerber H P, LeCouter J.
The biology of VEGF and its receptors.
Nat Med.
2003;
9
669-676
-
14
Gillies M C, Simpson J M, Luo W, Penfold P, Hunyor A B, Chua W, Mitchell P, Billson F.
A randomized clinical trial of a single dose of intravitreal triamcinolone acetonide for neovascular age-related macular degeneration: one-year results.
Arch Ophthalmol.
2003;
121
667-673
-
15
Gragoudas E S, Adamis A P, Cunningham Jr E T, Feinsod M, Guyer D R.
VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group: Pegaptanib for neovascular age-related macular degeneration.
N Engl J Med.
2004;
351
2805-2816
-
16
Grisanti S, Tatar O, Canbek S. et al .
Immunhistopathologic evaluation of choroidal neovascular membranes following verteporfin-photodynamic therapy.
Am J Ophthalmol.
2004;
137
914-923
-
17
Heier J S.
Review of Lucentis (ranibizumab, rhuFab V2) Phase I/II trial results: 6 month treatment of exsudative AMD.
IOVS.
2004;
45
1109
-
18 Heier J S. The VEGF antibody approach: the rhuFab collaborative trial. Rhu-Fab V2 for the treatment of wet AMD. American academy. Subspeciality Day. 2003
-
19 Heier J S. Lucentis update. American academy. Retina Subspeciality day. 2005
-
20
Holz F G, Pauleikhoff D, Klein R, Bird A C.
Pathogenesis of lesions in late age-related macular disease.
Am J Ophthalmol.
2004;
137
504-510
-
21
Holz F G, Bindewald A, Schutt F, Specht H.
Microablation of choroidal tissue by a 308 nm AIDA Excimer laser for RPE transplantation in patients with age-related macular degeneration.
Biomed Tech.
2003;
48
82-85
-
22 Holz F G, Pauleikhoff D, Spaide R F, Bird A C. Age-related macular degeneration. Berlin, Heidelberg, New York; Springer-Verlag 2004
-
23
Ishida S, Usui T, Yamashiro K. et al .
VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization.
J Exp Med.
2003;
198
483-489
-
24
Ishida S, Usui T, Yamashiro K. et al .
VEGF164 is proinflammatory in the diabetic retina.
Invest Ophthalmol Vis Sci.
2003;
44
2155-2162
-
25
Jaissle G B, Szurman P, Bartz-Schmidt K U.
Nebenwirkungen und Komplikationen der intravitrealen Triamcinolonacetonid-Therapie.
Ophthalmologe.
2004;
101
121-128
-
26
Jonas J, Kreissig I, Hugger P, Sauder G, Panda-Jonas S, Degenring R.
Intravitreal triamcinolone acetonide for exsudative age-related macular degeneration.
Br J Ophthalmol.
2003;
87
462-468
-
27
Jonas J, Kreissig I, Kamppeter B, Degenring R.
Intravitreales Triamcinolonacetonid zur Behandlung intraokulärer ödematöser und neovaskulärer Erkrankungen.
Ophthalmologe.
2004;
101
113-120
-
28
Jonas J, Kreissig I, Degenring R.
Factors influencing visual acuity after intravitreal triamcinolone acetonide treatment of exsudative age-related macular degeneration.
Br J Ophthalmol.
2004;
88
1557-1562
-
29
Jonas J B, Degenring R F, Kreissig I, Friedemann T, Akkoyun I.
Exsudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study.
Eye.
2005;
19
163-170
-
30
Joussen A M, Kirchhof B, Gottstein C.
Molekulare Mechanismen der Vaskulogenese und Angiogenese. Möglichkeiten antiangiogener Therapie.
Ophthalmologe.
2003;
100
(4)
284-291
-
31
Kaiser P K.
Verteporfin therapy in combination with triamcinolon: published studies investigating a potential synergistic effect.
Curr Med Res Opin.
2005;
21
705-713
-
32
Kim K J, Li B, Winer J. et al .
Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo.
Nature.
1993;
362
841-844
-
33 Klaver C CW. et al .Epidemiology of age-related maculopathy. Holz FG, Pauleikhoff D, Spaide RF, Bird AC Age-related macular degeneration. Berlin, Heidelberg, New York, Tokyo; Springer 2003
-
34
Kliffen M, Sharma H S, Mooy C M. et al .
Increased expression of angiogenetic growth factors in age-related maculopathy.
Br J Ophthalmol.
1997;
81
154-162
-
35
Ladewig M S, Ziemssen F, Jaissle G, Helb H M, Scholl H PN, Eter N, Bartz-Schmidt K U, Holz F G.
Intravitreales Bevacizumab bei der neovaskulären altersabhängigen Makuladegeneration.
Ophthalmologe.
2006;
103
463-470
-
36
Machemer R, Sugita G, Tano Y.
Treatment of intraocular proliferations with intravitreal steroids.
Trans Am Ophthalmol Soc.
1979;
77
171-180
-
37
Machemer R, Steinhorst U H.
Retinal separation, retinotomy, and macular relocation: II A surgical approach for age-related macular degeneration?.
Grafe's Arch Clin Exp Ophthalmol.
1993;
231
635-641
-
38
Macular Photocoagulation Study Group .
Argon laser photocoagulation for neovascular maculopathy: five year results from randomized clinical trial.
Arch Ophthalmol.
1991;
109
1109-1114
-
39
Macular Photocoagulation Study Group .
Laser photocoagulation for juxtafoveal choroidal neovascularisation: five year results from randomized clinical trial.
Arch Ophthalmol.
1994;
112
500-509
-
40
Macular Photocoagulation Study Group .
Visual outcome after laser photocoagulation for subfoveal choroidal neovascularisation secondary to age-related macular degeneration: the influence of initial lesion size and initial visul acuity.
Arch Ophthalmol.
1994;
112
480-488
-
41
Matsuoka M, Ogata N, Otsuji T. et al .
Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy.
Br J Ophthalmol.
2004;
88
809-815
-
42
Michels S, Rosenfeld P J, Puliafito C A. et al .
Systemic Bevacizumab (Avastin) for neovascular age-related macular degeneration. Twelve-week results of an uncontrolled open-label clinical study.
Ophthalmology.
2005;
112
1035-1047
-
43
Michels S, Rosenfeld P J.
Therapie der neovaskulären altersbedingten Makuladegeneration mit Ranibizumab/Lucentis.
Klin Monatsbl Augenheilkd.
2005;
222
480-484
-
44
Miller D W, Joussen A M, Holz F G.
Die molekularen Mechanismen der neovaskulären AMD.
Ophthalmologe.
2003;
100
(2)
92-96
-
45
Mordenti J, Cuthbertson R A, Ferrara N. et al .
Comparisons of the intraocular tissue distribution, pharmakokinetics and safety of 1251-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration.
Toxicol Pathol.
1999;
27
536-544
-
46
Okamoto N, Tobe T, Hackett S F. et al .
Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization.
Am J Pathol.
1997;
151
281-291
-
47
Pauleikhoff D, Bornfeld N, Gabel V-P, Holz F G, Roider H.
Konsenspapier der Retinologischen Gesellschaft, der Deutschen Ophthalmologischen Gesellschaft und des Berufsverbandes der Augenärzte: Stellungnahme zur aktuellen Therapie der neovaskulären AMD.
Klin Monatsbl Augenheilkd.
2005;
222
381-388
-
48
Penfold P, Gyory J, Hunyor A, Billson F.
Exsudative macular degeneration and intravitreal triamcinolone. A pilot study.
Aust N Z J Ophthalmol.
1995;
23
188-192
-
49
Rosenfeld P J, Villate N, Feuer W J. et al .
Rhu-Fab V2 (Anti-VEGF Antibody Fragment) in neovascular AMD: safety, tolerability and efficacy of multiple, escalating dose intravitreal injections.
IOVS.
2003;
44
970
-
50 Rosenfeld P J. Avastin for AMD. American Academy Retina Subspeciality Day. 2005
-
51 Schmidt-Erfurt U. Lucentis - A chance for visual improvement in neovascular age-related macular degeneration. Advanced retinal therapy meeting Vienna. 2005
-
52
Schwesinger G, Yee C, Rohan R M. et al .
Intrachoroideal neovascularization in transgenic mice overexpressing vascular endothelial growth factor in the retinal pigment epithelium.
AM J Pathol.
2001;
158
1161-1172
-
53
Shahar J, Avery R L, Heilweil G. et al .
Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin).
Retina.
2006;
26
262-269
-
54 Slakter J S. Retaane update. American academy Retina subspeciality day. 2005: 21-23
-
55
Spaide R F, Sorenson J, Maranan L.
Combined photodynamic therapy with verteporfin and intravitreal triamcinolone acetonide for choroidal neovascularization.
Ophthalmology.
2003;
110
(8)
1517-1525
-
56
Spaide R F, Sorenson J, Maranan L.
Photodynamic therapy with verteporfin combined with intravitreal triamcinolone acetonide for choroidal neovascularisation.
Ophthalmology.
2005;
112
(2)
301-304
-
57
Spilsbury K, Garrett K L, Shen W Y. et al .
Overexpression of vascular endothelial growth factor (VEGF) in the retinal pigment epithelium leads to the development of choroidal neovascularization.
Am J Pathol.
2000;
157
135-144
-
58
Submacular Surgery Trials Group .
SST-Report No. 13. Surgery for subfoveal choroidal neovascularization of age-related macular degeneration: ophthalmic findings.
Ophthalmology.
2004;
111 (11)
1967-1980
-
59
Bartz-Schmidt K, Bertram B, Birngruber R, Bornfeld N, Gabel V P, Holz F. et al .
Stellungnahme zu aktuellen therapeutischen Möglichkeiten bei der neovaskulären altersabhängigen Makuladegeneration.
Klin Monatsbl Augenheilkd.
2006;
223
271-278
-
60
Takeda A, Hata Y, Shiose S. et al .
Suppression of experimental choroidal neovascularization utilizing KDR selective receptor tyrosine kinase inhibitor.
Graefes Arch Clin Exp Ophthalmol.
2003;
241
765-772
-
61
Thumann G, Kirchhof B.
Transplantation von Irispigmentepithel.
Ophthalmologe.
2004;
101
882-885
-
62
Tilton R G, Chang K C, LeJeune W S. et al .
Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF.
Invest Ophthalmol Vis Sci.
1999;
40
689-696
-
63
Thakker G D, Hajjar D P, Muller W A. et al .
The role of phospatidylinositol 3-kinase in vascular endothelial growth factor signaling.
J Biol Chem.
1999;
274
10002-10007
-
64
The Inhibition Study in Ocular Neovascularization VEGF (V.I.S.I.O.N.) .
Clinical Trial Group: Enhanced efficacy associated with early treatment of neovascular age-related macular degeneration with pegaptanib sodium: An exploratory analysis.
Retina.
2005;
25
815-827
-
65
Treatment of Age-Related Macular Degeneration with Photodynamic Therapy Study Group (TAP) .
Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two year results of 2 randomized clinical trials-TAP Report 2.
Arch Ophthalmol.
2002;
119
198-207
-
66
Van Meurs J C, van den Biesen P R.
Autologous retinal pigment epithelium and choroid translocation in patients with exsudative age-related macular degeneration: short-term follow-up.
Am J Ophthalmol.
2003;
136
688-695
-
67
Völcker M, Peters S, Inhoffen W, Ziemssen F.
Früher antioxidativer Effekt - OCT-Monitoring nach intravitrealer Bevacizumab-Applikation.
Ophthalmologe.
2006;
103
476-483
-
68
Ziemssen F, Bartz-Schmidt K U, Grisanti S.
(Neben-)Wirkungen der VEGF-Inhibitoren.
Ophthalmologe.
2006;
103
484-492
Dr. Matthias Maier
Augenklinik rechts der Isar der Technischen Universität München
Ismaningerstraße 22
81675 München
Email: m.maier@lrz.tum.de
